Comparative safety of periablation anticoagulation strategies for atrial fibrillation: Data from a large multicenter study

PACE - Pacing and Clinical Electrophysiology

Volumn 37, Issue 6, 2014, Pages 665-673

  Arshad, Aysha ^a   Johnson, Christopher K ^a   Mittal, Suneet ^a   Buch, Eric ^b   Hamam, Ismail ^c   Tran, Thanh ^d   Shaw, Richard E ^a   Musat, Dan ^a   Preminger, Mark ^a   Sichrovsky, Tina ^a   Herweg, Bengt ^d   Shivkumar, Kalyanam ^b   Hummel, John ^c   Steinberg, Jonathan S ^a  

^a Arrhythmia Institute Valley Health System Valley Health System New York and Ridgewood   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

ablation; atrial fibrillation; pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; FISH OIL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION REACTION; BODY MASS; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FALSE ANEURYSM; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART TAMPONADE; HEMATOMA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERICARDIAL EFFUSION; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; EPIDEMIOLOGY; INCIDENCE; MORTALITY; MULTICENTER STUDY; RISK FACTOR; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; CATHETER ABLATION; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

EID: 84902363320     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12401     Document Type: Article

References (26)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
2. Gerstenfeld EP, Callans D, Dixit S, Lin D, Cooper J, Russo AM, Verdino R, et al. Characteristics of patients undergoing atrial fibrillation ablation: Trends over a seven-year period 1999-2005. J Cardiovasc Electrophysiol 2007; 18: 23-28.
3. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
4. Lip GY, Proclemer A, Dagres N, Bongiorni MG, Lewalter T, Blomstrom-Lundqvist C,. Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. Europace 2012; 14: 741-744.
5. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 9: 632-696. e21.
6. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556.
7. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O, Banna M, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009; 6: 1425-1429.
8. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531-2534.
9. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
10. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA,. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
11. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-1174.
12. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, Crawford T, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2012; 10: 483-489.
13. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, Hayano M, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012; 76: 2337-2342.
14. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F,. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 2012; 35: 29-33.
15. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105.
16. Haines DE, Stewart MT, Dahlberg S, Barka ND, Condie C, Fiedler GR, Kirchhof NA, et al. Microembolism and catheter ablation I: A comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia. Circ Arrhythm Electrophysiol 2013; 6: 16-22.
17. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
18. Abhishek F, Heist EK, Barrett C, Danik S, Blendea D, Correnti C, Khan Z, et al. Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. J Interv Card Electrophysiol 2011; 30: 211-215.
19. Gopinath D, Lewis WR, Di Biase L, Natale A,. Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: Special considerations. J Cardiovasc Electrophysiol 2011; 22: 236-239.
20. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, Hongo R, Beheiry S, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: Evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 5: 302-311.
21. Santangeli P, Di Biase L, Burkhardt JD, Natale A,. Catheter ablation of atrial fibrillation under therapeutic warfarin should be adopted worldwide: Let's stop waiting for Gadot. J Cardiovasc Electrophysiol 2013; 24: 516-518.
22. Kuwahara T, Takahashi A, Yoshihide T, Kobori A, Miyazaki S, Takei A, Fujino T, et al. Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration. J Cardiovasc Electrophysiol 2013; 24: 510-515.
23. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013; 6: 460-466.
24. Haines DE, Mead-Salley M, Salazar M, Marchlinski FE, Zado E, Calkins H, Yarmohmohmaddi H, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol 2013; 37: 233-239.
25. Musat DL, Mittal S, Cox S, Ferrara M, Arshad A, Preminger M, Sichrovsky T, et al. Frequency, characteristics, and timing of CIED remote monitoring detected urgent and emergent event notifications. In: Proceedings of the Heart Rhythm 2012 33rd Annual Scientific Sessions 2012.
26. Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, Daubert JP, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: A meta-analysis of observational studies. J Interv Card Electrophysiol 2013; 37: 213-221.